Denosumab Biosimilar Updates

​​​​​​​Celltrion Submits Denosumab BLA to FDA: On November 30, 2023, it was reported that Celltrion had completed submission of its application to the FDA for CT-P41, its denosumab biosimilar of Amgen’s PROLIA and XGEVA….
By: Goodwin
Previous Story

A GDPR for AI? Political Agreement Reached on the EU AI Act

Next Story

India’s Digital Personal Data Protection Act 2023 vs. the GDPR: A Comparison